Barclays analyst Luke Sergott raised the firm’s price target on Exact Sciences (EXAS) to $77 from $65 and keeps an Overweight rating on the shares following the earnings report.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences: Strong Q3 Performance and Promising Outlook Drive Buy Rating and Increased Price Target
- Exact Sciences Reports Record Q3 Revenue and Raises Guidance
- Closing Bell Movers: Palantir down 3% after earnings
- Exact Sciences reports Q3 EPS 28c, consensus 16c
- Exact Sciences now sees FY25 total revenue $3.22B-$3.235B, consensus $3.16B